Sei Investments Co. Sells 120,966 Shares of Vanda Pharmaceuticals Inc. $VNDA

Sei Investments Co. decreased its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 63.6% in the 1st quarter, Holdings Channel reports. The institutional investor owned 69,295 shares of the biopharmaceutical company’s stock after selling 120,966 shares during the period. Sei Investments Co.’s holdings in Vanda Pharmaceuticals were worth $479,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. AIGH Capital Management LLC acquired a new position in Vanda Pharmaceuticals in the fourth quarter valued at approximately $17,626,000. Inscription Capital LLC grew its holdings in Vanda Pharmaceuticals by 293.5% during the 4th quarter. Inscription Capital LLC now owns 63,878 shares of the biopharmaceutical company’s stock worth $563,000 after acquiring an additional 47,646 shares during the period. SG Americas Securities LLC acquired a new stake in Vanda Pharmaceuticals during the 4th quarter worth $95,000. Boothbay Fund Management LLC bought a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter valued at $72,000. Finally, Quarry LP bought a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter valued at $53,000. 88.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on VNDA shares. Wall Street Zen downgraded Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. HC Wainwright dropped their price objective on Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating for the company in a report on Monday, August 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th. Finally, B. Riley Financial restated a “buy” rating and set a $12.00 target price (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 10th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Vanda Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $13.70.

Vanda Pharmaceuticals Stock Up 3.8%

Shares of NASDAQ:VNDA opened at $5.22 on Friday. The company has a 50 day moving average price of $5.67 and a two-hundred day moving average price of $6.65. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.60 and a current ratio of 1.61. The company has a market capitalization of $315.62 million, a PE ratio of -1.13 and a beta of 0.64. Vanda Pharmaceuticals Inc. has a 52 week low of $4.27 and a 52 week high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.46). Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. The firm had revenue of $50.53 million during the quarter, compared to analyst estimates of $61.92 million. Analysts forecast that Vanda Pharmaceuticals Inc. will post -3 earnings per share for the current year.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.